10 GHP Biotechnology & Lifesciences Awards 2026 From its base in Michigan, BioLogic Pharma Solutions has served as one of the industry’s most promising medical affairs consulting firms since opening its doors in 2024. At its core, the firm supports precommercial, pre-clinical, and resource- constrained biotech and pharmaceuticals companies pioneering new, gamechanging therapies. Its work in fractional medical affairs is particularly notable, with the firm providing senior-level expertise to its clients on a scalable, as-needed basis. To find out more about this, we spoke with BioLogic’s CEO, Mary Hames. For a little over two years now, BioLogic has been revolutionising the way biotech and pharma companies approach product development, with its flexible model of project-based consulting eradicating the need for expensive and risky FTEs, ultimately making launching products faster, more efficient, and less expensive. To help clients achieve this, BioLogic’s consulting includes strategic planning, trial recruitment, patient identification, medical communications, and more. “We have diverse experience and skills aligned with what’s emerging in this market now: diagnostics, AI, clinical trial execution, KOL engagement, patient ID, and congress planning” - Mary Hames, CEO Making all of this possible is the ‘dream team’ behind BioLogic, comprising employees with decades of first-hand industry experience. The dream team excels in flexibility, knowledge of a client company’s therapeutic area, and understanding their business goals. Their work is deliberately designed as an alternative to traditional medical affairs staffing models, which are often too rigid or expensive for emerging companies, with every engagement focused on tailored, impact-driven execution Exploring this in more detail, Mary told us: “We offer a unique business model that provides comprehensive fractional medical affairs support, acting as an extension of our clients’ organisations. Our crossfunctional team seamlessly integrates with clients, adapting to their evolving needs while ensuring strategic alignment. This flexible, scalable approach optimizes resources, reduces financial risk, and enhances efficiency throughout the therapeutic development and regulatory process.” Guided by this unique approach, BioLogic has been making waves in the biotech and pharma space since the beginning, but this past year has marked a period of notable impact. . Among their achievements, BioLogic led national Phase 3 site outreach and feasibility efforts for a rare disease trial, leading to significant interest across the US, with approximately a third now enrolled or actively planning to participate. Building on this momentum, BioLogic created a new patient-facing website to support disease and study education. Building on its work identifying genetic testing gaps last year, BioLogic has also expanded its rare disease portfolio to include Coffin-Lowry syndrome (CLS). With no approved therapies and limited natural history data, BioLogic developed and presented a structured framework at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD, aimed at characterizing the natural history of CLS and integrating existing datasets to identify gaps and opportunities for drug development. The proposed framework offers a feasible path toward therapeutic readiness and supports earlyphase clinical trial design for a condition that has long lacked both a dedicated registry and measurable clinical endpoints. These capabilities position BioLogic as a meaningful partner for the biotech and pharma companies it serves, many of which are navigating rapid change while working to bring new products to market. In this environment, BioLogic’s scalable, flexible modelhelps clients deescalate high-pressure situations and manage complexity without sacrificing quality, despite limited funding and strict industry regulations. Dr. Hames was pleased to share that some of the programs BioLogic is making possible are unique treatments with a lot of potential. The firm’s work is conducted in full alignment with FDA, EMA, and GDPR standards, with the team actively engaging regulatory and advocacy organizations to ensure ongoing compliance and appropriate patient engagement. Clients benefit from a partner that consistently upholds and embodies the highest standards. Looking ahead, BioLogic’s goals for 2H 2026 and beyond include expanding its fractional medical affairs model to support more precommercial biotech companies. BioLogic is launching new tools, partnerships, and initiatives to speed drug development with fellow pioneers in the space. All of this will see the firm remain a beacon of trust for discerning companies looking for a measurable impact. Further information on BioLogic Pharma Solutions and its fractional medical affairs services can be found below. Contact: Mary Hames Company: BioLogic Pharma Solutions Web Address: https://biologicpharmasolutions.com/ Best Emerging Biotech & Pharmaceutical Consulting Firm 2026 – USA & GHP Client Service Excellence Award 2026 BioLogic Pharma Solutions
RkJQdWJsaXNoZXIy MTUyMDQwMA==